# Administrative Supplement: Early Career Cancer Clinical Investigator Award (ECIA)

> **NIH NIH P30** · EMORY UNIVERSITY · 2024 · $59,999

## Abstract

PROJECT SUMMARY/ABSTRACT
Dr. Manali Bhave is an academic medical oncologist with a research focus on early phase therapeutic
clinical trial development involving novel targeted therapies and immunomodulatory strategies for the
treatment of breast cancer. Her goal is to lead institutional investigator-initiated and NCI-sponsored
cooperative group clinical trials that will further advance the fight against cancer. Dr. Bhave plays a
critical role in Winship’s clinical trial program and is extensively involved in NCI-sponsored clinical
trials. She is an active member on multiple national committees including the Breast Cancer Working
Groups for SWOG and ETCTN, and plans to expand her involvement with ECOG-ACRIN and her role
within ETCTN as Emory’s Breast lead. She is the institutional principal investigator of two NCI-
sponsored clinical trials, three investigator-initiated clinical trials at Winship and one investigator-
initiated clinical trial currently under development through SWOG. She also contributes as an active
co-investigator on numerous others. As a phase I and breast oncology leader at Winship, Dr. Bhave
is an important contributor to patient enrollment to NCTN and ETCTN trials. She is Vice Chair of
Winship’s Data & Safety Monitoring Committee, Medical Director of the Phase I Clinical Trials Unit
and Phase I Working Group Lead. In these roles, she has shown tremendous growth as a leader to
broaden the clinical trial portfolio, improve access to phase I clinical trials, and increase faculty
engagement in the Phase I program. Winship Cancer Institute of Emory University fully supports Dr.
Bhave in her career goals to advance as a national leader in clinical trials for breast cancer and early
phase therapeutics, and in her ongoing efforts to enhance the clinical trial program at Winship. The
ECIA award will support protected time for Dr. Bhave to focus on key initiatives to increase trial
accrual at Winship through building a stronger phase I clinical trials infrastructure, and further develop
her own promising protocol concepts at the national level. The ECIA funding mechanism will
undoubtedly help foster academic growth and lead to further leadership roles within Winship and the
NCI Trial Networks.

## Key facts

- **NIH application ID:** 11001803
- **Project number:** 3P30CA138292-15S1
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Suresh S Ramalingam
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $59,999
- **Award type:** 3
- **Project period:** 2009-04-07 → 2028-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11001803

## Citation

> US National Institutes of Health, RePORTER application 11001803, Administrative Supplement: Early Career Cancer Clinical Investigator Award (ECIA) (3P30CA138292-15S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11001803. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*